IPP Bureau

Shilpa Biologicals' PartnerPower promises real-time transparency in biologics development
Shilpa Biologicals' PartnerPower promises real-time transparency in biologics development

By IPP Bureau - June 23, 2026

New digital platform provides global sponsors with live visibility into R&D, process development and GMP manufacturing operations, enhancing collaboration and decision-making

KIMS Hospitals launches RENOVA Oncology Institute in Bengaluru
KIMS Hospitals launches RENOVA Oncology Institute in Bengaluru

By IPP Bureau - June 23, 2026

KIMS RENOVA Oncology Institute, in association with the Samrohana Cancer Foundation, announced the “134 Free Screening Camp Pledge”,

Teva submits FDA application for experimental Tourette syndrome treatment ecopipam
Teva submits FDA application for experimental Tourette syndrome treatment ecopipam

By IPP Bureau - June 23, 2026

The filing is backed by positive Phase 3 results recently published in JAMA Neurology

FDA advisory panel backs Moderna flu vaccine candidate for older adults
FDA advisory panel backs Moderna flu vaccine candidate for older adults

By IPP Bureau - June 23, 2026

The backing comes as influenza remains a persistent public health burden

FDA clears 131 drugs as global pharma approval momentum rebounds in 2025
FDA clears 131 drugs as global pharma approval momentum rebounds in 2025

By IPP Bureau - June 23, 2026

After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average

Roche’s Lunsumio VELO–Polivy combo moves closer to FDA decision after strong lymphoma trial results
Roche’s Lunsumio VELO–Polivy combo moves closer to FDA decision after strong lymphoma trial results

By IPP Bureau - June 23, 2026

The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines

WuXi Biologics wins fourth EMA certification for Suzhou Biosafety Center
WuXi Biologics wins fourth EMA certification for Suzhou Biosafety Center

By IPP Bureau - June 23, 2026

Clearing 19 biologics for Europe market

ZEISS and Envision Health Technologies team up to push VR-based glaucoma testing forward
ZEISS and Envision Health Technologies team up to push VR-based glaucoma testing forward

By IPP Bureau - June 23, 2026

The move comes as demand rises for wider access to glaucoma screening and more flexible clinical workflows

Biopharma funding rebounds in 2026, but capital flows to lower-risk assets
Biopharma funding rebounds in 2026, but capital flows to lower-risk assets

By IPP Bureau - June 22, 2026

M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges

Saurabh Gambhir elevated to Chief Strategy Officer (Global) at Cipla
Saurabh Gambhir elevated to Chief Strategy Officer (Global) at Cipla

By IPP Bureau - June 22, 2026

Prior to joining Cipla, Gambhir built a strong track record across the pharmaceutical and healthcare sectors.

MICK Digital empanelled as AMTZ authorized channel partner
MICK Digital empanelled as AMTZ authorized channel partner

By IPP Bureau - June 22, 2026

Partnership strengthens healthcare technology distribution capabilities, enabling wider reach of Make-in-India medical devices through government and institutional healthcare networks

BPL Medical honours strategic partners with Pinnacle Awards 2026
BPL Medical honours strategic partners with Pinnacle Awards 2026

By IPP Bureau - June 22, 2026

The company hosted Symbiosis 2026 at its 2-acre manufacturing facility in Bengaluru, inaugurated in 2024

Aurobindo Pharma USA secures FTC clearance for $250 million Lannett acquisition
Aurobindo Pharma USA secures FTC clearance for $250 million Lannett acquisition

By IPP Bureau - June 22, 2026

Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility

CENT expands to Delhi-NCR with new clinical prevention centre in Gurugram
CENT expands to Delhi-NCR with new clinical prevention centre in Gurugram

By IPP Bureau - June 22, 2026

New Gurugram centre is India's first clinical Prevention Centre with 2 state of the art MRI machines and a capacity of 2000 scans a month

Nearly half of cardiac investigations in men above 30 show abnormalities, claims report
Nearly half of cardiac investigations in men above 30 show abnormalities, claims report

By IPP Bureau - June 22, 2026

Study of 78,000 diagnostic investigations by Mahajan Imaging identifies over 13,000 abnormal or critical findings, highlighting silent health risks among working-age men

Latest Stories

Interviews

Packaging